Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
Abstract Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and rarely an absence of free light chains in the serum and urine. Given its rarity, the genomic landscape, clinical course, and prognosis of...
Guardado en:
Autores principales: | Ashiq Masood, Trevor Christ, Samia Asif, Priya Rajakumar, Beth A. Gustafson, Leyla O. Shune, Ameen Salahudeen, Drew Nedvad, Suparna Nanua, Agne Paner, Timothy M. Kuzel, Mia Levy, Janakiraman Subramanian, Shahzad Raza |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/31e8f416ebe34f07bee1c287af92fbac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu VW, et al.
Publicado: (2018) -
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018) -
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019) -
Targeted inhibition in tumors with ALK dependency
por: Kwak EL, et al.
Publicado: (2013) -
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock AB, et al.
Publicado: (2020)